about
Buprenorphine for the management of opioid withdrawalBuprenorphine for the management of opioid withdrawalA multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials NetworkSubstance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependenceUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceImproving temporal efficiency of outpatient buprenorphine induction.Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trialCombat posttraumatic stress disorder, substance use disorders, and traumatic brain injuryAttitudes toward buprenorphine and methadone among opioid-dependent individuals.Practical considerations for the clinical use of buprenorphine.Effects of Smoking Cessation on Illicit Drug Use among Opioid Maintenance Patients: A Pilot Study.Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network.Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.Spontaneous reductions in smoking during double-blind buprenorphine detoxification.Opioid dependence treatment: options in pharmacotherapy.The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells.Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.Buprenorphine: new treatment of opioid addiction in primary care.Opioids and the treatment of chronic pain: controversies, current status, and future directions.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058Therapeutic options and challenges for substances of abuse.The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy."Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.Comparing buprenorphine induction experience with heroin and prescription opioid users.Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.Initiation of buprenorphine during incarceration and retention in treatment upon release.Retention in methadone and buprenorphine treatment among African Americans.
P2860
Q24240149-E031F4FD-DD4E-403F-84DD-9F3CC266E507Q24246088-63C7CA0B-4B19-42F9-A17D-F0DF4C57F331Q24548339-A6FB7752-C804-4A04-95CB-4BDE94D43C1AQ24805157-9F1FFB9C-E2B4-4A03-B47B-B8F2B27D8FF7Q26865674-96DA944A-5A1D-4F13-ACCD-7878D15CDE33Q30425074-33A4E290-1CC5-4D58-89B3-1DBA3F101B7BQ30432435-DCC58097-125C-4D60-9053-3CF4719A940EQ30433266-142B9068-C67D-4355-99D4-5B684DBB2915Q33621921-6F37BFCB-684F-4DEF-BA57-F546AB1EA129Q33774853-AD7FEB19-31F2-4A05-A732-B35535679562Q33792307-F05A500D-0659-4990-B292-97CEC114E153Q33793165-0AC89E1E-38C1-4C7E-9491-67AB0E47C64FQ33837577-D1552041-8504-4990-85A9-ABE97A890BB7Q33853121-1A22595F-AAB5-4679-9677-490961EC63E2Q33868638-46D99BCA-86FF-4911-8381-CC0937E5217EQ33889324-F95B9599-AC86-4BCB-B439-3D8EC211E7EDQ34081656-B37C965D-AA85-4CF5-9BFE-3E5F59069678Q34138291-02A04CFF-F229-481C-879E-CEDD9E831725Q34186492-46828BEF-7647-462E-99F5-8A6A31BD3449Q34359979-E52B16DC-AE1C-4B68-B0B2-08975D374558Q34485532-19D576CD-0E70-488F-A618-3185420ADBB0Q34667890-4410B3FB-E481-4D96-9636-E30CB8573402Q34846394-F4931A71-E3F6-4B24-83D5-37E4C1408C79Q35160035-C593C017-185A-44F9-99B4-36FFEE81A127Q35244943-EC6438A6-09F7-4923-9FA2-8378522DA568Q35454891-318F9177-62E6-4EFA-88D0-69FA388CFA05Q35491054-DC2CA22B-2113-403C-8C7B-EC2CB237393DQ35608547-A1E96F96-A970-4E27-A534-BC698ACC34A4Q35687716-0520FFD5-1EFA-4DAF-984B-446203BD45F7Q35923078-66BF90A9-75F3-4A94-8AAD-9D2522C5F4D2Q35954416-FB91DDB7-26F6-43E7-901F-8329E4B48A37Q36021346-067D5019-2DBF-48D5-8EC7-2B8BB86E2AB1Q36110773-9C352EE1-333F-4252-8F0D-FBFECB88E635Q36394429-43001B9C-1E2D-406D-8BE5-16F0E1E71B94Q36627877-4DEE2AC3-96A8-4F28-B039-AED9FF278B53Q36655057-848175A7-603A-4E80-8859-7E4568CC41DEQ36779246-4245B12D-0BEE-4740-8AA5-F39D4009C990Q36845718-02162582-910A-49F3-8869-9A7491B01669Q36948204-830709A9-EC56-4CAA-9B89-68C4DD2C7B53Q37022122-9B3B0489-92A8-48D6-9428-19F4E8FFAD17
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Buprenorphine: how to use it right.
@ast
Buprenorphine: how to use it right.
@en
type
label
Buprenorphine: how to use it right.
@ast
Buprenorphine: how to use it right.
@en
prefLabel
Buprenorphine: how to use it right.
@ast
Buprenorphine: how to use it right.
@en
P2093
P1476
Buprenorphine: how to use it right.
@en
P2093
Eric C Strain
Leslie Amass
Rolley E Johnson
P304
P356
10.1016/S0376-8716(03)00060-7
P433
P577
2003-05-01T00:00:00Z